Treatment of chronic hepatitis B: Case selection and duration of therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 4, 2002, Pages 409-414

  Leung, Nancy ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antiviral treatment; Case selection; Chronic hepatitis B; Combination therapy; Interferon; Lamivudine; Treatment course

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; THYMIDINE; THYMOSIN ALPHA1;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; EARLY DIAGNOSIS; HEPATITIS B; HERBAL MEDICINE; HUMAN; IMMUNOMODULATION; LIVER CELL; LIVER CIRRHOSIS; LIVER FAILURE; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; SEROCONVERSION; SIDE EFFECT; TREATMENT INDICATION; VIREMIA; VIRUS REPLICATION;

EID: 0036104753     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02767.x     Document Type: Conference Paper

References (24)

1. Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection
2. Biological basis for the clinical use of interferon
3. 2-interferon in Chinese patients with chronic hepatitis B infection
4. Effect of alfa-interferon treatment in patients with hepatitis B e antigen-positive hepatitis B: Meta-analysis
5. Liver disease: Significant improvement with lamivudine
6. Management of chronic hepatitis B. Nucleoside analogues in the treatment of chronic hepatitis B
7. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B
8. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
9. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong
10. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia
11. The treatment of chronic viral hepatitis
12. A preliminary trial of lamivudine for chronic hepatitis B infection
13. A one-year trial of lamivudine for chronic hepatitis B
14. Efficacy and tolerability of two years of lamivudine therapy in Asian patients with chronic hepatitis B
15. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis e antigen seroconversion rates: Results after three years of therapy
16. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine
17. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B
18. Two sensitive PCR-based methods for the detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
19. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
20. The effect of longer duration of harbouring lamivudine resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years lamivudine therapy in Chinese patients
21. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
22. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection
23. Evolving therapies for the treatment of chronic hepatitis B virus infection
24. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: A meta-analysis